Chief Medical Officer, Airfinity Ltd., UK. Professor of Vascular Disease, University of Copenhagen, DK
Are GLP-1a's and maybe other AOM's the "new statins" for CVD prevention? New data from SELECT indicate other mechanisms for prevention than mere weight loss! Join us discussing this and other intriguing findings on Wednesday 22nd of May.
New #data from the SELECT trial was released at the recent European Congress on Obesity. The most compelling findings reported were by John Deanfield et al, showing that cardiovascular prevention in the trial was unrelated to baseline BMI and magnitude of weight loss during the trial. The authors concluded that the data suggests alternative mechanisms of improved cardiovascular outcome beyond reduction in adiposity, which may benefit many patients on top of current guideline-directed care. On Wednesday 22 May, Henrik Sillesen will be hosting an exclusive fireside chat two key industry leaders Mads Tang-Christensen and Klaus Langhoff-Roos where we will delve into these findings further, as well as showcasing new benchmarking data. Sign up for free here: https://lnkd.in/e-5UQZrw European Association for the Study of Obesity (EASO) #glp1 #obesity #pharma #lifesciences #publichealth